Pemigatinib Efficacy: Significantly Improving Survival in FGFR2-Fusion Cholangiocarcinoma

　　Pemigatinib,a highly selective FGFR inhibitor,provides a crucial targeted therapy option for patients with advanced cholangiocarcinoma harboring FGFR2 gene fusions or rearrangements.Its efficacy is primarily assessed via imaging,with key metrics including objective response rate,disease control rate,progression-free survival,and overall survival.

　　The pivotal Phase II FIGHT-202 study established pemigatinib's efficacy profile.In this trial involving patients with FGFR2-fusion/rearranged cholangiocarcinoma who had failed at least one prior line of therapy,pemigatinib(13.5mg once daily on a 2-weeks-on/1-week-off schedule)demonstrated significant anti-tumor activity.The results showed an objective response rate of 35.5%,meaning over one-third of patients experienced significant tumor shrinkage(including 2.8%complete responses and 32.7%partial responses).The disease control rate was 82.2%.More notably,the median progression-free survival reached 6.9 months,and the median overall survival was extended to 21.1 months,representing a substantial improvement over historical data for conventional chemotherapy.

　　Efficacy is closely tied to specific biomarkers.Pemigatinib is most effective for patients with FGFR2 fusions,also shows activity against FGFR2 rearrangements,but is largely ineffective against FGFR2 point mutations,underscoring the necessity of precise genetic testing before treatment initiation.

　　Patient survival benefit is directly correlated with the depth of treatment response.Patients achieving a partial response had a median progression-free survival of 12.2 months,indicating the most significant benefit.Furthermore,the onset of hyperphosphatemia(a side effect related to the drug's on-target activity)during treatment may be associated with better treatment response.In the FIGHT-202 study,the median duration of response was 7.2 months,with approximately 30%of responders continuing to benefit after one year of treatment.However,most patients eventually develop resistance,commonly through secondary FGFR2 mutations.

　　The efficacy of pemigatinib has been validated in studies across multiple global regions,including real-world evidence in Asian populations,which is consistent with the key clinical trial findings.Proactively managing treatment-related side effects(e.g.,hyperphosphatemia,stomatitis)to maintain treatment continuity is crucial for achieving long-term benefit.Overall,for patients with FGFR2-fusion/rearranged cholangiocarcinoma who have limited treatment options,pemigatinib represents the current standard targeted therapy,significantly improving survival outcomes.